CSF2 and congenital rubella syndrome: In addition to the use of inhibitory receptors, removing genes encoding cytokines such as GM-CSF, which has the potential to drive clinical CRS or neurotoxicity with CRISPR-Cas9, results in safe, potent and durable cell products [193].